

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

## Proactive healthcare for frail elderly persons – study protocol for a prospective controlled primary care intervention in Sweden

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-027847
Article Type:	Protocol
Date Submitted by the Author:	10-Nov-2018
Complete List of Authors:	Marcusson, Jan; Clinicial & Experimental Medicine, Geriatrics Nord, Magnus; Department of Medical and Health Sciences, Family Medicine Johansson, Maria; Clinicial & Experimental Medicine, Geriatrics Alwin, Jenny; Department of Medical and Health Sciences, Health Care Analysis Levin, Lars-Åke; Department of Medical and Health Sciences, Health Care Analysis Dannapfel, Petra; Clinicial & Experimental Medicine, Geriatrics Thomas, Kristin; Department of Medicine and Health Sciences, Linköpin University Poksinska, Bozena Bonnie; Linkopings universitet, Management and Engineering Sverker, Annette; Department of Medicine and Health Sciences, Linköping University, Rehabilitation Medicine Olaison, Anna; Social and Welfare Studies Cedersund, Elisabet; Social and Welfare Studies Motel-Klingebiel, Andreas; Social and Welfare Studies Hellström, Ingrid; Department of Social and Welfare Studies Böttiger, Ylva; Department of Medicine and Health Sciences, Linköping University, Kulberg, Agneta; Social and Welfare Studies Böttiger, Ylva; Department of Medicine and Health Sciences, Linköping University, Clinícal Pharmacology Dong, Huan-Ji; Department of Medicine and Health Sciences, Linköping University, Physiotherapy Wass, Malin; Research and Development Unit in Region Östergötland Andersson, Agneta; Research and Development Unit in Region Östergötland Andersson, Agneta; Research and Development Unit in Region Östergötland
Keywords:	health care, fragile, elderly

1 2 3 4 5 6 7 8 9	SCHOLARONE <sup>™</sup> Manuscripts
10 11 12 13 14 15 16 17 18 19	
20 21 22 23 24 25 26 27 28 29	
30 31 32 33 34 35 36 37 38 39	
40 41 42 43 44 45 46 47 48 49	
50 51 52 53 54 55 56 57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## Proactive healthcare for frail elderly persons – study protocol for a prospective controlled primary care intervention in Sweden

Corresponding author:

Jan Marcusson

Postal address: Geriatric Medicine, University Hospital, SE 58185 Linköping, Sweden,

e-mail jan.marcusson@liu.se

Phone + 46 70 5717033,

Jan Marcusson<sup>1</sup>, Magnus Nord<sup>2</sup>, Maria Johansson<sup>1</sup>, Jenny Alwin<sup>3</sup>, Lars-Åke Levin<sup>3</sup>, Petra Dannapfel<sup>1</sup>, Kristin Thomas<sup>4</sup>, Bonnie Poksinska<sup>5</sup>, Annette Sverker<sup>6</sup>, Anna Olaison<sup>7</sup>, Elisabet Cedersund<sup>8</sup>, Susanne Kelfve<sup>8</sup>, Andreas Motel-Klingebiel<sup>8</sup>, Ingrid Hellström<sup>9</sup>, Agneta Kullberg<sup>10</sup>, Ylva Böttiger<sup>11</sup>, Huan-Ji Dong<sup>12</sup>, Anneli Peolsson<sup>13</sup>, Malin Wass<sup>14</sup>, Johan Lyth<sup>14</sup> and Agneta Andersson<sup>14</sup>

- 1. Geriatric Medicine, Department of Clinical and Experimental Medicine, Linköping University
- 2. Family Medicine, Department of Medical and Health Sciences, Linköping University
- 3. Division of Health Care Analysis, Department of Medical and Health Sciences, Linköping University
- 4. Department of Medical and Health Sciences, Linköping University
- 5. Department on Management and Engineering, Linköping University
- 6. Department of Rehabilitation Medicine Department of Medical and Health Sciences, and Department of Social and Welfare Studies Linköping University.
- Department of Social and Welfare Studies, Linköping University, Linköping and CESAR- Centre for Social Work, Uppsala University
- 8. Ageing and Social Change, Department of Social and Welfare Studies, Linköping University
- 9. Department of Social and Welfare Studies, Linköping University
- 10. Division of Community Medicine, Department of Medical and Health Sciences, Linköping University
- 11. Clinical Pharmacology, Department of Medical and Health Sciences, Linköping University
- 12. Department of Medical and Health Sciences, Linköping University
- 13. Physiotherapy, Department of Medical and Health Sciences, Linköping University
- 14. Research and Development Unit in Region Östergötland and Department of Medical and Health Sciences, Linköping University.

Word Count. 4709

## ABSTRACT

**Introduction:** The present provision of services is not dedicated to promoting the maintenance of function and does not target frail older persons at high risk of the main causes of morbidity and mortality. Therefore, the aim of this study is to evaluate the effects of a proactive intervention in comparison with conventional care to a group of persons aged 75 and older selected by statistical prediction.

Methods and analysis: In a pragmatic multicentre primary care setting (n = 1600), a prediction model to find elderly (75+) persons at high risk of complex medical care or hospitalisation is used, followed by proactive medical and social, in comparison to usual care. The study started in April 2017 with a run-in period until December 2017, followed by a two-year continued intervention phase that will continue until the end of December 2019. The intervention includes several tools (multi-professional team for rehabilitation, social support, medical care home visits, telephone support etc.). Primary outcome measures are: healthcare cost, number of hospital care episodes, hospital care days and mortality. Secondary outcomes are: number of outpatient visits, cost of social care and informal care, number of prescribed drugs, health-related quality of life (HRQoL), cost-effectiveness, sense of security, functional status and ability. We also study the care of elderly persons in a broader sense, covering the perspectives of the patients, the professional staff and of the management and political level, by using semi-structured interviews, qualitative methods and a questionnaire.

**Ethics and dissemination:** Approved by the regional ethical review board in Linköping (Dnr 2016/347-31). The results will be presented in scientific journals and scientific meetings during 2019–2022 and are planned to be used for the development of future care models.

**Trial registration.** Enhanced primary care for the elderly. Clinical Trials Gov ID: NCT03180606

Key words. health care fragile elderly

## Strengths and limitations of the study

- This study is a pragmatic clinical trial on proactive healthcare for people 75 years and older in primary care, meaning that it has a close connection with clinical reality, which will enhance any future implementation
- The case-finding method is a statistical prediction model which allows the "screening" of large numbers of patients

- The developed clinical evaluation and management model integrates primary care with community care and social services
- The project also focuses on the perspectives of the patients, the professionals in the healthcare system and the governance mechanisms, which may explain the perceived shortcomings of today's healthcare for the elderly
- A fairly long run-in period due to clinical realities and organisational inertia in the healthcare system as well as a long intervention period of two years are clinical necessities, but this increases the risk of non-controlled influences on the project

to beet terien only

#### INTRODUCTION

The healthcare situation of the elderly is a challenge for healthcare systems in many countries, and healthcare providers struggle to meet the needs of a growing number of older people<sup>1</sup>. In Sweden, the largest consumers of medical services (60%) are persons 80 years and older (15% of the population), a group that is predicted to increase by 50% over the next 15 years. Several studies report that a majority of the aged population is satisfied with their health<sup>2</sup>, manage life at home and consider themselves healthy<sup>34</sup>. Only a minority of the aged population is in need of hospital care. In most cases, the healthcare system does not distinguish between different groups among the heterogeneous old-age population; instead, both hospital and primary care are organised using a passive and reactive (acting when symptoms or problems occur) approach. There have been many attempts to define and measure frailty among the elderly in order to detect persons with significant care needs (e.g.<sup>5</sup>. However, "frailty" is difficult to define as a medical condition and there is no consensus on the operational definition of the concept <sup>6</sup>. Furthermore, scale evaluation requires a manual resource utility for each individual evaluation, which is not easily applied within a broader clinical context that lacks a primary geriatric perspective (e.g. primary care and acute ward disciplines).

The current healthcare system in many countries is not designed to identify individuals with healthcare needs or to direct care resources towards those with the greatest need for care prior to hospitalisation. Since the use of "frailty scales" involves merely a fraction of the flow of hospitalised elderly, statistical prediction models have been proposed as an effective means of evaluating larger target groups to enable resource-limited interventions for those with the greatest needs <sup>7</sup>. However, the clinical use of prediction in routine clinical primary care of the elderly remains to be clarified. Proactive interventions provided to the elderly within a certain age-range, and/or with multi-morbidity but with low predictive value for hospitalisation, may direct healthcare resources towards groups that are not in most need of them. Likewise, interventions for small, specific groups (e.g. newly hospitalised, specific medical diagnoses or patients above a certain frailty index score) will neglect large groups of elderly in need of healthcare or miss the larger care-flows of geriatric hospital care.

This study will evaluate whether a proactive primary care intervention into a predicted risk population of the elderly results in care that is more effective and of higher quality than that of a control group who receive standard care. In addition, in a set of parallel sub-studies, factors that may facilitate or act as barriers to the development of healthcare for older persons will be studied from several perspectives, including those of the elderly themselves and of the healthcare of the elderly.

## METHOD AND ANALYSIS

The study consists of two parallel lines of research. The first, linked to the primary scientific question, is an intervention study of proactive care for older persons in primary care. The second is a set of sub-studies on different perspectives of elderly care, ranging from the patient, the professionals and governance to societal aspects.

## Patient involvement

The public was represented health care politicians with responsibility for health care for elderly. They supervised, participated in the construction of and approved the aims and the contents of the study. They follow they progress of the project every 6 months. The patient's perspective of the study is obtained by in-depth interviews at different time points of the study.

## Intervention study of proactive care for older persons in primary care

## Primary scientific question

Can the prediction of fragile older individuals at high risk of hospital care, combined with proactive healthcare, lead to a decrease in healthcare utilisation and costs?

## Design, randomisation and setting

This intervention study is designed to follow a shift in the paradigm of elderly care that had already been decided by the care providers. This led us to use a study design that enables us to detect the real-world effectiveness of the intervention in a broad patient group in a real, non-selected clinical context with clinically meaningful outcome parameters. Consequently, our design follows a selected pragmatic clinical trial model, in which defined primary care health centres using the new work routines constitute our intervention group and the remaining centres are used as controls <sup>8</sup>.

The pragmatic clinical trial follows the fact that the intervention to be provided is close to the future *modus operandi* of healthcare for the elderly, but it still allows a scientific evaluation before it is implemented further in healthcare organisations. It is a prospective, controlled, multicentre study performed in primary care centres in south-east Sweden. A case-finding algorithm (prediction for hospital care) is used to identify eligible persons within the whole population in the region. The intervention will be performed at nine selected primary care centres (provided by the sponsoring County Council of Östergötland), and the predicted patients there form the intervention group. A similar number of control patients with similar risk scores (for hospitalisation) are predicted in healthcare centres with similar characteristics

to the intervention centres, but they receive care as usual, and these centres are not made aware of the control patients. There is no randomisation at the patient level, but the casefinding algorithm was used in the selection and the patients with the highest risk scores were included until the preferred number of patients was reached. There was no randomisation of healthcare centres; these were provided by the healthcare sponsor (County Council of Östergötland). The control healthcare centres were matched in terms of location (city, countryside), size and socio-economic distribution.

#### Sample size

A pilot study (not published) showed that 60% of the target population had at least one hospitalisation during a 12-month period. The hypothesis is that this figure will be reduced by 20% in the intervention group in this study. A sample size calculation based on this reduction, a power of 0.8 and a significance level of 0.05 led to a minimum of 270 participants per group. Considering the frail and elderly population, we estimate a 40% dropout rate and we have therefore increased the sample size to 378 per group. Since we are using a pragmatic clinical trial design, featuring heterogeneity within both the participating population and the participating healthcare centres, this reduces the likelihood of detecting meaningful changes; therefore, it is reasonable to double the number of participants per group, giving a final number of 800 included individuals per group.

#### **Prediction of patient cases**

The prediction model is described elsewhere (manuscript submitted). In short, the data was obtained between November 2015 and October 2016 from the computerised information system of the County Council of Östergötland, where statistics for all the healthcare in the county is stored. For example, for the whole population there are records of: number of visits to primary or hospital care, number of days in hospital, diagnostic codes for each visit, etc. We used an in-ward hospital stay between November 2016 and January 2017 as the dependent variable. The prediction variables are based on a previous study <sup>4</sup>, including number of GP visits and International Classification of Diseases, 10th Revision, (ICD-10) codes, use of assistive technology, emergency room (ER) visits, age and gender. The aim is to identify participants aged 75 or older who are likely to be hospitalised during the next three months. Risk scores were calculated for all individuals using logistic regression. Individuals were ranked according to the risk scores (for hospital care), from high to low. A cut-off value was chosen so that 800 individuals from the participating healthcare centres with the highest scores were selected for proactive intervention for a period of two years. The same cut-off value was then used to choose individuals from the control healthcare centres.

#### Evaluation form.

A four-page evaluation form has been developed and is used to standardise the evaluation of each individual (the Primary Care Assessment Tool for the Elderly- PASTEL). The goal is to create a time-efficient, easy-to-use tool for a doctor-nurse team. It is intended to be used by primary care nurses and doctors with different levels of experience. The PASTEL form is

based on the holistic approach of Comprehensive Geriatric Assessment (CGA) <sup>6</sup> and includes different aspects of health and function that are often of importance to the older patient. It also includes the Clinical Frailty Scale <sup>9</sup>.

The form contains three parts. The first consists of an interview guide with mostly multiplechoice questions and a self-rating of health. The second part is a checklist for a brief physical examination and laboratory testing, a medication review and questions about the individual's opinion about their present and future needs for care. The third part is used for a team meeting to make a common estimation of frailty and to decide on the need for further investigation and actions to support the elderly person.

#### Intervention

The intervention group is approached by a primary care team, who evaluates the client's social and medical condition and establishes a proactive care plan for individuals in need. The primary care team is represented by the general practitioner (GP) responsible for the patient, a registered nurse (RN) dedicated to elderly care and, when needed, a physiotherapist, occupational therapist and/or social worker. The proactive intervention consists of a complete check-up/follow-up and intervention into medical, psychiatric, functional and social aspects of the client in a stepwise, resource-differentiated way according to needs based on the clinical judgement of the team (Fig. 2). The evaluation process used communication over the phone as well as visits to the primary care centre, depending on the priority of the client's needs. Examples of common actions/measures are: evaluation of medication, initiation of home care, diet counselling, advice on physical activity and support for loneliness and isolation. The formation of an "elderly team" with dedicated nurses who function as personal nurses for the frail individuals is the key component of the intervention, together with the standardised evaluation of frailty based on comprehensive geriatric assessment.

#### Outcome measures for intervention

Primary outcome measures are: healthcare cost, number of hospital care episodes, hospital care days and mortality. Secondary outcomes are: number of outpatient visits, cost of social care and informal care, number of drugs, number of prescribed drugs not recommended for the elderly, health-related quality of life (HRQoL), cost-effectiveness, sense of security and functional ability.

Data on healthcare consumption will be obtained from the administrative healthcare database and data on healthcare costs from the cost-per-patient database. Cost for social care and informal care will be estimated by number of contacts multiplied by a defined unit cost. Use of medications at the group level will be studied by extracting group data from the National Medication Database, before, during and after the study.

## Statistical analysis for intervention study

*Primary outcomes*. Primary outcome measures for intervention vs control population (healthcare cost, number of hospital care episodes, hospital care days and mortality) will consist of analyses for years 1 and 2 respectively, using the intention to treat (ITT) and last observation carried forward (LOCF) method. Differences in means and proportions between groups will be analysed using a t-test. Differences in categorical data will be analysed using a Chi-squared test. If the baseline mean risk score differs between the intervention and control groups, primary outcomes adjusted for risk score will be analysed using linear or logistic regression.

## Monitoring

Every six months, each primary care centre is monitored by the project group, providing opportunities for dialogue and problem solving. Every six months, or earlier when needed, each primary care centre reviews the patients included in the study and actions are considered depending on the results of the review. Every six months, the primary care teams gather for a network meeting to discuss common issues and share experiences.

## Data management

No biomaterials are included in the study. All patient data will be processed lawfully according to the General Data Protection Regulation (GDPR). The data file used for the prediction model, for the intervention group and the control group was retrieved from Region Östergötland's administrative databases. The data file that will be used for analysis in both the main study and the sub-studies contains personal data from Region Östergötland's administrative databases as well as data reported by the patient. The file will only be available to the overall project manager and individuals responsible for each sub-project, i.e. the co-authors of this paper. The file will be stored in databases with a high level of security at Region Östergötland and Linköping University and also protected by personal passwords. Questions regarding data are replied to through the corresponding author upon request. We used the SPIRIT reporting guidelines <sup>10</sup>.

# Sub-studies on different perspectives of elderly care, from patient to professionals and governance to societal aspects.

#### **Scientific questions**

What are the experiences of the previous and new healthcare model for older people from a wider individual, social, professional and societal perspective? What are the governance mechanisms that may facilitate or act as barriers to the development of healthcare for older people? What is the cost-effectiveness of the intervention in comparison to care as usual?

Based on these overall questions, there are four main research perspectives with specific research questions:

- 1. The perspective of the older patients and their families: How does the change in healthcare provision towards proactive primary elderly care impact upon individual participation and subjective well-being as well as objective indicators of quality of life beyond health? How does the change in healthcare provision towards proactive primary elderly care shape the receipt of informal help and support from spouses, offspring and the wider network? How can the change result in socially structured outcomes, how does the focusing of care contribute to the life-course accumulation of (dis)advantage in old age and how does this contribute to social inequality dynamics? Studied through a questionnaire from the patient's perspective, in-depth patient data and interviews from the patient's perspective.
- 2. The professional perspective on the healthcare system: How does the change in healthcare provision towards proactive primary elderly care change the satisfaction and support of the professionals within the healthcare system? Qualitative studies of selected parts of the healthcare system, i.e. using a shadowing method targeting the home-care organisation that is experienced by the nurses who are shadowed, and implementation studies using semi-structured interviews. An implementation study explores the organisational readiness to implement the new work routines in primary care. Investigating organisational readiness can provide knowledge about early factors that are important for implementation. Also, most of the care given to the frail elderly occurs outside of the primary care setting. The municipality is responsible for care at home and in nursing homes. Another research question is therefore concerned with how collaboration is organised between primary care and social care.
- 3. *The governance perspective:* What are the mechanisms and explanations for today's elderly care, from the political level down to operative healthcare management? Implementation studies using semi-structured interviews.
- 4. *Cost-effectiveness:* What is the cost-effectiveness of the intervention compared to usual care? Data will be collected through questionnaires and registries.

## Methods for sub-studies

*Questionnaire for the patient's perspective and in-depth patient data.* We will study how the change in healthcare provision impacts upon individual well-being, the support they receive from their private networks of families and friends and their satisfaction with and the support of the healthcare system. A longitudinal study design enables us to follow changes over time. Moreover, we will analyse whether the focusing of care contributes to the life-course accumulation of (dis)advantage in old age and how this contributes to social inequality dynamics. The longitudinal patient questionnaire study collects data on three occasions, t1– t3, over a period of 36 months. The information from the questionnaires will be combined with a registry-based assessment of social-structure and life-course information at t1 and referenced with nationally representative life-course data on health, occupation and family from Statistics Sweden (SCB) and the National Board of Health and Welfare (Socialstyrelsen). Measures in the questionnaire include the EQ-5D-3L and EQ-VAS <sup>11</sup> for health-related quality of life (HRQoL) estimates, activities of daily living/functions by the ADL Staircase <sup>12</sup> and RAND-36 for self-reported functional health <sup>13</sup>. A measure for sense of security in care is also used (SECP) <sup>14</sup>. The dizziness handicap inventory is used to detect

the presence of a risk of falls <sup>15</sup> and its related health consequences. A visual analogue scale (0–100 mm) and a pain-drawing instrument is used to evaluate pain experience <sup>16</sup>.

Interviews from the patient's perspective. In one sub-project, we focus on how frail older people experience care services if included in the intervention. Twenty semi-structured interviews with elderly patients will be conducted. A selection of elderly patients will be made, and this selection will include patients who have experiences of the intervention. Interviews are intended to provide access to the feelings, thoughts and experiences of patients. The starting point is that the interview is a knowledge-producing activity, and it is during the interview and in the interaction with the individual and the researcher that knowledge is produced <sup>17</sup>. Another sub-project aims to investigate how the elderly experience their everyday lives and the opportunities for rehabilitation from an availability and participation perspective. Do the elderly receive the rehabilitation they consider themselves to need? A qualitative study with a strategic selection of approximately 20 participants from the intervention group will be conducted.

*Qualitative studies of selected parts of the healthcare system.* A qualitative approach (shadowing) <sup>18</sup> is used to study the working conditions for nurses in primary care in relation to challenges in their professional responsibility connected to their work. The proposed subproject addresses key issues in order to obtain knowledge about how competence levels and the distribution of tasks match the needs of frail older people living at home. The ongoing development in the field of the care of older people can be studied through the concept of task-shifting <sup>19</sup>. Questions of task shifting are implicit in discussions concerning the relationship between general competence and specialist competence within professional groups or the resource deficit in relation to ageing populations. The main aim is therefore to explore and characterise task-shifting processes in practices, competencies, responsibilities and roles from the perspective of registered nurses working within the main project. A second aim is to explore the challenges of handling drugs and the pharmaceutical preparations related to nurse practices in home care, and how these challenges are processed.

*Implementation studies*. In order to meet the future challenges posed by an ageing population, it is not only important to develop and evaluate new care models, but also to ensure that these models are implemented successfully by organisations providing care. Three separate studies investigate the implementation of the new work routines for improved care among the frail elderly.

To study the implementation of the model, the project will use a framework that specifies four types (or domains) of determinants, which function as barriers and/or facilitators for successful implementation. Research in implementation science has established that successful implementation depends on an interplay between these determinants: (1) the effectiveness of the strategies chosen to support the implementation; (2) the characteristics of the new practices (routines, methods, etc.) being implemented; (3) beliefs, attitudes and motivations among the front-line implementers; and (4) the context of the implementation. The framework will provide a basic structure of interviews which will be carried out with representatives of different levels of the healthcare system: from political leadership and primary-care management to practitioners on the front line of primary care. Study I focuses

on the role of professionals in implementing the new work routines, including adopting a holistic approach to care. This study also investigates readiness to change at both an individual level (e.g. resources, attitudes) and an organisational level (e.g. system that support change).

Study II. Preliminary results from Study I indicate that successful collaboration between primary care providers and the municipalities is essential in achieving proactive care and implementing the new work routines. Indeed, most care of the frail elderly occurs outside of a primary care setting. The second study therefore investigates these conditions or collaborations via interviews with managers representing both organisations. A concept mapping approach will be used to identify and quantify the factors affecting implementation. Interviews will be audio-recorded and transcribed verbatim.

Finally, a third study will focus on investigating the governance mechanisms that influence the present situation as well as the uptake of new models through policy-making and implementation. Despite good intentions and various policies, Swedish elderly care has not undergone any extensive change; thus, the same challenges and development needs are being discussed today as 20 years ago.

For this reason, this sub-project will investigate the mechanisms that facilitate or impede evidence-based policy-making and implementation from the political level to the regional level in elderly care. Questions that will be studied are: What influences policy-making and implementation at different levels? What are the strategies for policy implementation? How is policy implementation monitored and evaluated at different levels? Three levels of policy-making and implementation will be studied. Level 1: politicians and Ministry of Health and Social Affairs. Level 2: state agencies and authorities at national level, i.e. NBHW (Socialstyrelsen) and the Swedish Association of Local Authorities and Regions. Level 3: politicians, executive boards and managers at county council and regional level. Interviews will be audio-recorded and transcribed verbatim.

#### Statistical analysis for sub-studies

The outcomes of the sub-studies are: number of outpatient visits, cost of social and informal care, number of drugs, number of prescribed drugs not recommended for the elderly, health-related quality of life (HRQoL), cost-effectiveness, sense of security and functional ability. The measures will be analysed for years 1 and 2 respectively using the intention to treat (ITT) and last observation carried forward (LOCF) method. Differences between groups will be analysed using a t-test. We intend to estimate the cost-effectiveness in terms of cost/QALY (quality-adjusted life years) from a lifetime perspective using simulation models. The QALY weights will be obtained from the EQ-5D-3L.

## Time plan

An overview is presented in Fig. 1. The project started with the development of the case-finding algorithm (manuscript in progress) in 2017. Based on this model, the case-finding process was undertaken at the beginning of March 2017.

Selected patients were presented to each healthcare centre for the start of the intervention programme in April 2017. A run-in period of April–December 2017 was used, during which

healthcare centres were informed about and introduced to the new work model, and patients were subsequently enrolled onto the programme. All selected high-risk patients will have received an initial healthcare and/or social care plan. More than 90% of the selected patients were included by the end of December 2017. The intervention/follow-up period is planned to last for two years, until the end of 2019 (Fig 1).

An initial questionnaire was sent to all selected patients in the intervention and control healthcare centres during May–June 2017. The questionnaire will also be distributed to enrolled participants in years 2 and 3. Interviews with professionals in participating primary care health centres and communities were performed during June–September 2017. Interviews with elderly participants in order to capture the patient's perspective on the study were performed during December 2017–July 2018. Interviews with elderly participants in order to capture the patient's perspective on rehabilitation will take place during November 2018–February 2019. Interviews with high-level decision-makers and politicians were conducted during January–September 2018.

A first preliminary outcome analysis after 13 months of intervention will be performed in January 2019. The intervention and collection of healthcare data ends on 31 December 2019. The analysis of primary and secondary outcome measures starts in 2020. The scientific writing-up and participation in academic conferences has already started for some of the sub-projects. The writing period for the intervention study begins in spring 2020. Dialogue with owners/stakeholders at a political level takes place every six months during the course of the project.

Possible evidence for changes in elderly care across the whole County of Östergötland will be available in autumn 2020, when the implementation process of the new care model can be broadened. Members of the research group are participating in workshops at a national level concerning healthcare development.

Figure 1. Overview of the project over time.

Figure 2. Overview of the intervention.

#### Ethics and dissemination

This study was subject to ethical evaluation and approved by the regional ethical review board in Linköping (Dnr 2016/347-31). They judged all aspects of the study including design and safety. By adding an academic study to an ongoing change in the healthcare process for the elderly, we do not per se include or exclude treatment possibilities for individuals or groups of individuals. The study itself is "inert" within the healthcare system. Therefore, we do not see that the use of aggregated patient data from the healthcare system can be of any harm to the participants. On the contrary, we find strong ethical motives for the study, which is an academic attempt to detect the real-world effectiveness of a politically determined intervention into a large patient group. The patients who responded to the questionnaire did so using an informed consent.

> The data will be presented in scientific journals and communicated at scientific meetings during the period 2018–2022. The outcome data of the study will be presented to the healthcare provider (County Council of Östergötland) for a discussion on the evidence relating to future care models for elderly persons. The data will also be used by healthcare managers and decision-makers for the development of future care models.

upin ersons. . developme

## DISCUSSION

Clinical trials on complex healthcare processes are rare and difficult to design with adequate scientific quality. On the other hand, delimited clinical trials may also only be valid within an academic setting and the outcome difficult to reproduce in clinical reality. In order to counteract the scientific challenges facing trials in complex clinical settings and processes, the use of a pragmatic clinical trial design is one, or perhaps the only, alternative <sup>8</sup>. In terms of the primary context of elderly care, this study is intended to find answers to basic scientific questions about the future healthcare of the elderly.

One challenge for the study was to find older patients in need of healthcare, hopefully before escalating needs would develop. Managing thousands of patients during this screening for possible illness may be impossible in healthcare using face-to-face methods. Statistical models for case findings have recently proven valid and are recommended in the clinical healthcare of old persons <sup>7</sup> so this *modus operandi* was used in this study.

There is a great need for improved healthcare for the elderly and a simultaneous knowledge gap regarding scientific data on what care models to use in the future. This study aims to fill some of that gap and may hopefully generate some clinically meaningful data that can be used for the future development of healthcare for older persons.

#### **Authors contributions**

Jan Marcusson: principal investigator, design, analysis and scientific writing.

Magnus Nord: clinical project leader, design, clinical site visits, data collection, analysis, scientific writing

Ylva Böttiger: design, analysis, scientific writing

Huan-Ji Dong: design and analysis of prediction model. Scientific writing.

Maria Johansson, Anneli Peolsson: clinicians and scientists responsible for rehabilitation, design of the postal questionnaire, data collection, analysis, scientific writing

Jenny Alwin, Lars-Åke Levin: design and health economic analysis, design of the postal questionnaire, data collection, analysis, scientific writing

Petra Dannapfel, Kristin Thomas, Bonnie Poksinska, design and analysis of implementation studies, data collection, analysis, scientific writing

Annette Sverker, Anna Olaison, Elisabet Cedersund, design of interviews and analysis of the patient's perspective, scientific writing

Susanne Kelfve, Andreas Motel-Klingebiel: design of postal questionnaire, analysis of wellbeing, network support, satisfaction and social inequality based on questionnaire and registry data, scientific writing

Ingrid Hellström, Agneta Kullberg: design and analysis of professional perspective, scientific writing

Johan Lyth analysis, scientific writing

Malin Wass, project-coordinator, scientific writing

Agneta Andersson: co-investigator, analysis, scientific writing

#### **Funding statement**

This work was supported by the County Council of Östergötland and Linköping University from the strategic research fund for 'Health Care and Welfare' [Grant number 2016186-14]. Contact person is Dean Johan Söderholm, Deans office, Medical Faculty, Linköping University. This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

Competing interests: None.

## REFERENCES

- 1. Banerjee S. Multimorbidity—older adults need health care that can count past one. *Lancet* neurology 2015;385(9967):587-89. doi: doi:10.1016/S0140-6736(14)61596-8
- Soong J, Poots AJ, Scott S, et al. Developing and validating a risk prediction model for acute care based on frailty syndromes. *BMJ open* 2015;5(10):e008457. doi: 10.1136/bmjopen-2015-008457 [published Online First: 2015/10/23]
- Collerton J, Davies K, Jagger C, et al. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. *Bmj* 2009;339:b4904. doi: 10.1136/bmj.b4904 [published Online First: 2009/12/24]
- 4. Nagga K, Dong HJ, Marcusson J, et al. Health-related factors associated with hospitalization for old people: comparisons of elderly aged 85 in a population cohort study. *Archives of gerontology and geriatrics* 2012;54(2):391-7. doi: 10.1016/j.archger.2011.04.023 [published Online First: 2011/06/07]
- Edmans J, Bradshaw L, Franklin M, et al. Specialist geriatric medical assessment for patients discharged from hospital acute assessment units: randomised controlled trial. *Bmj* 2013;347:f5874. doi: 10.1136/bmj.f5874 [published Online First: 2013/10/10]
- 6. Ellis G, Whitehead MA, Robinson D, et al. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. *Bmj* 2011;343:d6553. doi: 10.1136/bmj.d6553 [published Online First: 2011/10/29]
- 7. NICE. National Institute for Clinical Excellence. Multimorbidity: clinical assessment and management (NICE clinical guideline 56), 2016.
- 8. Ford I, Norrie J. Pragmatic Trials. *New England Journal of Medicine* 2016;375:454-63. doi: 10.1056/NEJMra1510059
- Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. *The journal of nutrition, health & aging* 2012;16(7):601-8. [published Online First: 2012/07/28]
- 10. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Annals of internal medicine* 2013;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583 [published Online First: 2013/01/09]
- 11. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. *Health policy* 1990;16(3):199-208. [published Online First: 1990/11/05]
- 12. Sonn U, Asberg KH. Assessment of activities of daily living in the elderly. A study of a population of 76-year-olds in Gothenburg, Sweden. *Scandinavian journal of rehabilitation medicine* 1991;23(4):193-202. [published Online First: 1991/01/01]
- 13. Orwelius L, Nilsson M, Nilsson E, et al. The Swedish RAND-36 Health Survey reliability and responsiveness assessed in patient populations using Svensson's method for paired ordinal data. *J Patient Rep Outcomes* 2017;2(1):4. doi: 10.1186/s41687-018-0030-0 [published Online First: 2017/01/01]
- 14. Krevers B, Milberg A. The instrument 'sense of security in care--patients' evaluation': its development and presentation. *Psycho-oncology* 2014;23(8):914-20. doi: 10.1002/pon.3502
- 15. Jacobson GP, Calder JH. A screening version of the Dizziness Handicap Inventory (DHI-S). *The American journal of otology* 1998;19(6):804-8. [published Online First: 1998/11/27]
- 16. Margolis RB, Tait RC, Krause SJ. A Rating System for Use with Patient Pain Drawings. *Pain* 1986;24(1):57-65. doi: Doi 10.1016/0304-3959(86)90026-6
- 17. Patton MQ. Qualitative research & evaluation methods. London: SAGE 2002
- 18. Macdonald S. Studying actions in a context: a qualitative shadowing method for organizational research. *Qualitative research* 2005;5:455-73.
- 19. WHO. Task shifting: Rational redistribution of tasks among health workforce teams: Global recommendations and guidelines. Geneva: World Health Organization, 2008.

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
14	
15	
16	
17	
17	
18	
19	
20	
21	
22	
~~	
23	
24	
27	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	


> For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

to been teriew only

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	Rum-in period with inclusion of patients - April 2017 - December 2017
11	Ongoing intervention – January 2018 - December 2019
12	
13	Patients list Prioritisation Patient Visit/ Acture/ Personalized healthcare contact examination medical healthcare
14	Contact examination assessment plan
15	
16	
17	Main study     Implementation of the new work model     Algorithm for selection of target group     Baseline questionnaire     Follow-up questionnaire 1     Follow-up questionnaire 2     Analysis of outcome variables
18	study of the new work selection of questionnaire questionn
19	
20	Auturno 2016 - Spring 2017 Spring 2017 - Auturno 2017 Auturno 2017 - Spring 2018 Spring 2018 - Auturno 2018 - Auturno 2018 - Spring 2019 - Auturno 2019
21	1 April 2017 – Start of the Intervention 1 January 2018 - 70% of 1 Decarate 2019 - selected patients neclived Data collection ends
22	secto pisenta receveo usas contection enos intervention
23	Scientific writing
24	
25	
26	
27	
28	
28	
30	Figure 1. Overview of the preject over time
31	Figure 1. Overview of the project over time.
32	254x190mm (96 x 96 DPI)
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52	
53 54	
55	
56	
57	
58	
59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
00	

BMJ Open: first published as 10.1136/bmjopen-2018-027847 on 22 May 2019. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

**BMJ** Open



58 59

60




Figure 2. Overview of the intervention.

195x159mm (72 x 72 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

 Page
 Number

 Title
 #1
 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
 1

 Trial registration
 #2a
 Trial identifier and registry name. If not yet registered, name of intended registry
 2

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2	Trial registration:	<u>#2b</u>	All items from the World Health Organization Trial	n/a
3 4 5 6 7 8 9 10 11 12 13 14 15 16	data set		Registration Data Set	
	Protocol version	<u>#3</u>	Date and version identifier	n/a
	Funding	<u>#4</u>	Sources and types of financial, material, and other support	15
	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	1, 14
	responsibilities:			
17 18 19	contributorship			
20 21 22	Roles and	<u>#5b</u>	Name and contact information for the trial sponsor	15
22 23 24	responsibilities:			
24 25 26	sponsor contact			
20 27 28 29	information			
30 31 32 33 34 35 36 37 38	Roles and	<u>#5c</u>	Role of study sponsor and funders, if any, in study design;	15
	responsibilities:		collection, management, analysis, and interpretation of	
	sponsor and funder		data; writing of the report; and the decision to submit the	
			report for publication, including whether they will have	
39 40			ultimate authority over any of these activities	
41 42				
43 44	Roles and	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating	14
45 46	responsibilities:		centre, steering committee, endpoint adjudication	
47 48	committees		committee, data management team, and other individuals or	
49 50			groups overseeing the trial, if applicable (see Item 21a for	
51 52 53			data monitoring committee)	
54 55	Background and	<u>#6a</u>	Description of research question and justification for	4-5
56 57 58	rationale		undertaking the trial, including summary of relevant studies	
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3			(published and unpublished) examining benefits and harms for each intervention	
4 5 7 8 9 10 11	Background and rationale: choice of	<u>#6b</u>	Explanation for choice of comparators	5-6
	comparators			
12 13 14 15	Objectives	<u>#7</u>	Specific objectives or hypotheses	5
16 17 18 19 20	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel	5
			group, crossover, factorial, single group), allocation ratio,	
20 21 22			and framework (eg, superiority, equivalence, non-inferiority,	
23 24			exploratory)	
25 26 27	Study setting	<u>#9</u>	Description of study settings (eg, community clinic,	5
27 28 29	<i>y</i> 0		academic hospital) and list of countries where data will be	
30 31			collected. Reference to where list of study sites can be	
32 33 34			obtained	
35 36	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable,	6
37 38 39		<u></u>	eligibility criteria for study centres and individuals who will	Ū
40 41			perform the interventions (eg, surgeons, psychotherapists)	
42 43				_
44 45 46	Interventions:	<u>#11a</u>	Interventions for each group with sufficient detail to allow	7
47 48	description		replication, including how and when they will be	
49 50			administered	
51 52 53	Interventions:	<u>#11b</u>	Criteria for discontinuing or modifying allocated	n/a
54 55	modifications		interventions for a given trial participant (eg, drug dose	
56 57			change in response to harms, participant request, or	
58 59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2018-027847 on 22 May 2019. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

1 2			improving / worsening disease)	
3 4	Interventions:	<u>#11c</u>	Strategies to improve adherence to intervention protocols,	n/a
5 6 7 8 9	adherance		and any procedures for monitoring adherence (eg, drug	
			tablet return; laboratory tests)	
10 11 12	Interventions:	<u>#11d</u>	Relevant concomitant care and interventions that are	n/a
13 14 15	concomitant care		permitted or prohibited during the trial	
16 17	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the	7
18 19 20			specific measurement variable (eg, systolic blood pressure),	
20 21 22			analysis metric (eg, change from baseline, final value, time	
23 24			to event), method of aggregation (eg, median, proportion),	
25 26			and time point for each outcome. Explanation of the clinical	
27 28 29			relevance of chosen efficacy and harm outcomes is strongly	
30 31			recommended	
32 33 34	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any	11-12
35 36			run-ins and washouts), assessments, and visits for	
37 38 39			participants. A schematic diagram is highly recommended	
40 41 42			(see Figure)	
42 43 44	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study	6
45 46			objectives and how it was determined, including clinical and	
47 48			statistical assumptions supporting any sample size	
49 50 51			calculations	
52 53 54	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to	n/a
55 56			reach target sample size	
57 58				
59 60	I	<sup>=</sup> or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Allocation: sequence	<u>#16a</u>	Method of generating the allocation sequence (eg,	n/a
3 4 5 7 8 9 10 11	generation		computer-generated random numbers), and list of any	
			factors for stratification. To reduce predictability of a random	
			sequence, details of any planned restriction (eg, blocking)	
			should be provided in a separate document that is	
12 13			unavailable to those who enrol participants or assign	
14 15 16 17			interventions	
18 19	Allocation	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg,	n/a
20 21	concealment		central telephone; sequentially numbered, opaque, sealed	
22 23	mechanism		envelopes), describing any steps to conceal the sequence	
24 25 26			until interventions are assigned	
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	Allocation:	<u>#16c</u>	Who will generate the allocation sequence, who will enrol	n/a
	implementation		participants, and who will assign participants to	
			interventions	
	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg,	n/a
			trial participants, care providers, outcome assessors, data	
			analysts), and how	
43 44	Blinding (masking):	<u>#17b</u>	If blinded, circumstances under which unblinding is	n/a
45 46	emergency		permissible, and procedure for revealing a participant's	
47 48 49	unblinding		allocated intervention during the trial	
50 51 52	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline,	8
53 54			and other trial data, including any related processes to	
55 56			promote data quality (eg, duplicate measurements, training	
57 58 59			of assessors) and a description of study instruments (eg,	
59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2018-027847 on 22 May 2019. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

1 2 3 4 5 6 7			questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	
, 8 9	Data collection plan:	<u>#18b</u>	Plans to promote participant retention and complete follow-	n/a
10 11	retention		up, including list of any outcome data to be collected for	
12 13			participants who discontinue or deviate from intervention	
14 15 16 17 18			protocols	
	Data management	#19	Plans for data entry, coding, security, and storage, including	8
19 20	Data managoment	<u>" 10</u>	any related processes to promote data quality (eg, double	0
21 22			data entry; range checks for data values). Reference to	
23 24 25			where details of data management procedures can be	
26 27			found, if not in the protocol	
28 29				
30 31	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary	8
32 33 34			outcomes. Reference to where other details of the statistical	
35 36			analysis plan can be found, if not in the protocol	
37 38	Statistics: additional	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and	n/a
39 40 41	analyses		adjusted analyses)	
42 43	Ctatiatian analysis	#20-	Definition of each reis non-ulation relating to protocol non	2
44 45	Statistics: analysis	<u>#20c</u>	Definition of analysis population relating to protocol non-	n/a
46 47	population and		adherence (eg, as randomised analysis), and any statistical	
48 49	missing data		methods to handle missing data (eg, multiple imputation)	
50 51 52	Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC); summary	8
53 54	formal committee		of its role and reporting structure; statement of whether it is	
55 56			independent from the sponsor and competing interests; and	
57 58			reference to where further details about its charter can be	
59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			found, if not in the protocol. Alternatively, an explanation of	
3 4			why a DMC is not needed	
5 6 7	Data monitoring:	<u>#21b</u>	Description of any interim analyses and stopping guidelines,	12
8 9	interim analysis		including who will have access to these interim results and	
10 11 12			make the final decision to terminate the trial	
13 14	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing	n/a
15 16 17 18 19 20 21 22 23 24			solicited and spontaneously reported adverse events and	
			other unintended effects of trial interventions or trial conduct	
	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any,	8
			and whether the process will be independent from	
25 26			investigators and the sponsor	
27 28		#0.4		10
29 30	Research ethics	<u>#24</u>	Plans for seeking research ethics committee / institutional	12
31 32	approval		review board (REC / IRB) approval	
33 34 35	Protocol	<u>#25</u>	Plans for communicating important protocol modifications	n/a
35 36 37	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
38 39			relevant parties (eg, investigators, REC / IRBs, trial	
40 41 42			participants, trial registries, journals, regulators)	
43 44 45	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential	12
45 46 47			trial participants or authorised surrogates, and how (see	
48 49			Item 32)	
50 51 52	Consent or assent:	#26b	Additional consent provisions for collection and use of	12
52 53 54		<u>#200</u>	participant data and biological specimens in ancillary	12
55 56	ancillary studies			
57 58			studies, if applicable	
59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2018-027847 on 22 May 2019. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

1 2	Confidentiality	<u>#27</u>	How personal information about potential and enrolled	n/a
3 4			participants will be collected, shared, and maintained in	
5 6			order to protect confidentiality before, during, and after the	
7 8 9			trial	
10 11 12	Declaration of	<u>#28</u>	Financial and other competing interests for principal	15
13 14 15	interests		investigators for the overall trial and each study site	
16 17 18	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset,	8
19 20			and disclosure of contractual agreements that limit such	
21 22			access for investigators	
23 24 25	Ancillary and post	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for	n/a
26 27	trial care		compensation to those who suffer harm from trial	
28 29 30			participation	
31 32 33 34 35 36 37 38 39	Dissemination policy:	<u>#31a</u>	Plans for investigators and sponsor to communicate trial	12-13
	trial results		results to participants, healthcare professionals, the public,	
			and other relevant groups (eg, via publication, reporting in	
			results databases, or other data sharing arrangements),	
40 41 42			including any publication restrictions	
43 44 45	Dissemination policy:	<u>#31b</u>	Authorship eligibility guidelines and any intended use of	n/a
45 46 47	authorship		professional writers	
48 49 50	Dissemination policy:	<u>#31c</u>	Plans, if any, for granting public access to the full protocol,	n/a
51 52	reproducible		participant-level dataset, and statistical code	
53 54	research			
55 56 57	Informed consent	#32	Model consent form and other related documentation given	n/a
58 59				11/a
60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1	materials	to participants and authorised surrogates
2 3 4 5 6 7 8 9 10 11 12 13 14	Biological specimens #33	Plans for collection, laboratory evaluation, and storage of n/a biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable
	The SPIRIT checklist is distril	buted under the terms of the Creative Commons Attribution License CC-
15 16	BY-ND 3.0. This checklist car	be completed online using <u>https://www.goodreports.org/</u> , a tool made
$\begin{array}{c} 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 48\\ 46\\ 47\\ 48\\ 48\\ 48\\ 46\\ 47\\ 48\\ 48\\ 48\\ 48\\ 48\\ 48\\ 48\\ 48\\ 48\\ 48$	by the <u>EQUATOR Network</u> in	collaboration with Penelope.ai
49 50 51 52 53 54 55 56 57 58 59 60	For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# **BMJ Open**

## Proactive healthcare for frail elderly persons – study protocol for a prospective controlled primary care intervention in Sweden

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-027847.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Feb-2019
Complete List of Authors:	Marcusson, Jan; Clinicial & Experimental Medicine, Geriatrics Nord, Magnus; Department of Medical and Health Sciences, Family Medicine Johansson, Maria; Clinicial & Experimental Medicine, Geriatrics Alwin, Jenny; Department of Medical and Health Sciences, Health Care Analysis Levin, Lars-Åke; Department of Medical and Health Sciences, Health Care Analysis Dannapfel, Petra; Clinicial & Experimental Medicine, Geriatrics Thomas, Kristin; Department of Medicale and Health Sciences, Linköping University Poksinska, Bozena Bonnie; Linkopings universitet, Management and Engineering Sverker, Annette; Department of Medicine and Health Sciences, Linköping University, Rehabilitation Medicine Olaison, Anna; Social and Welfare Studies Cedersund, Elisabet; Social and Welfare Studies Motel-Klingebiel, Andreas; Social and Welfare Studies Hellström, Ingrid; Department of Social and Welfare Studies Böttiger, Ylva; Department of Medicine and Health Sciences, Linköping University, Clinical Pharmacology Dong, Huan-Ji; Department of Medicine and Health Sciences, Linköping University, Clinical Pharmacology Pools, Anneli; Department of Medicine and Health Sciences, Linköping University, Manetare Studies Böttiger, Ylva; Department of Medicine and Health Sciences, Linköping University Peolsson, Anneli; Department of Medicine and Health Sciences, Linköping University Peolsson, Anneli; Department of Medicine and Health Sciences, Linköping University, Physiotherapy Wass, Malin; Research and Development Unit in Region Östergötland Lyth, Johan; Research and Development Unit in Region Östergötland Andersson, Agneta; Research and Development Unit in Region Östergötland
<b>Primary Subject Heading</b> :	General practice / Family practice
Secondary Subject Heading:	Geriatric medicine, Medical management
Keywords:	health care, elderly, frail

1	
2 3	
4	
5	
6	
7 8	SCHOLARONE <sup>™</sup>
9	Manuscripts
10	
11	
12 13	
13	
15	
16	
17	
18 19	
20	
21	
22	
23	
24 25	
26	
27	
28	
29 30	
31	
32	
33	
34 35	
36	
37	
38	
39 40	
41	
42	
43	
44 45	
46	
47	
48	
49 50	
51	
52	
53	
54 55	
55 56	
57	
58	
59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
00	to peer even only integrange entring complete about guidelines within

3	
4	1
5 6	2
7	3
8 9	4
10 11	5
12 13	6
14 15	7
16 17	7 8 9
18	9
19 20	10
21 22	11
23 24	12
25	13
26	14
27 28	15
29	16
30	17
31 32	
32 33	18 19 20
34	20 21
35	22
36 37	22 23 24
38	24 25
39	25
40 41	27
42	28
43	29 30
44 45	31
46	32 33
47	33 34
48 49	35
50	36
51 52	
53 54	37
55	38
56 57	
58	
59	
60	

## Proactive healthcare for frail elderly persons – study protocol for a prospective controlled primary care intervention in Sweden

5 Corresponding author:

6 Jan Marcusson

> Postal address: Acute Internal Medicine and Geriatrics, University Hospita 14th floorl, SE 58185 Linköping, 8 Sweden,

9 e-mail jan.marcusson@liu.se

10 Phone + 46 70 5717033.

Jan Marcusson<sup>1</sup>, Magnus Nord<sup>2</sup>, Maria Johansson<sup>1</sup>, Jenny Alwin<sup>3</sup>, Lars-Åke Levin<sup>3</sup>, Petra 12 Dannapfel<sup>1</sup>, Kristin Thomas<sup>4</sup>, Bonnie Poksinska<sup>5</sup>, Annette Sverker<sup>6</sup>, Anna Olaison<sup>7</sup>, Elisabet 13 14 Cedersund<sup>8</sup>, Susanne Kelfve<sup>8</sup>, Andreas Motel-Klingebiel<sup>8</sup>, Ingrid Hellström<sup>9</sup>, Agneta Kullberg<sup>10</sup>, Ylva Böttiger<sup>11</sup>, Huan-Ji Dong<sup>12</sup>, Anneli Peolsson<sup>13</sup>, Malin Wass<sup>14</sup>, Johan Lyth<sup>14</sup> 15 and Agneta Andersson<sup>14</sup> 16

> 1. Acute Internal Medicine and Geriatrics, Department of Clinical and Experimental Medicine, Linköping University

- 2. Family Medicine, Department of Medical and Health Sciences, Linköping University
- 3. Division of Health Care Analysis, Department of Medical and Health Sciences, Linköping University
- Department of Medical and Health Sciences, Linköping University 4.
- 5. Department on Management and Engineering, Linköping University
  - 6. Department of Rehabilitation Medicine Department of Medical and Health Sciences, and Department of Social and Welfare Studies Linköping University.
    - 7. Department of Social and Welfare Studies, Linköping University, Linköping and CESAR- Centre for Social Work, Uppsala University
    - Ageing and Social Change, Department of Social and Welfare Studies, Linköping University 8.
    - 9. Department of Social and Welfare Studies, Linköping University
    - 10. Division of Community Medicine, Department of Medical and Health Sciences, Linköping University
    - 11. Clinical Pharmacology, Department of Medical and Health Sciences, Linköping University
    - 12. Department of Medical and Health Sciences, Linköping University
    - 13. Physiotherapy, Department of Medical and Health Sciences, Linköping University
    - 14. Research and Development Unit in Region Östergötland and Department of Medical and Health Sciences, Linköping University.

#### Word Count. 4838

2		
2	39	
4	59	
5 6	40	ABSTRACT
7	41	Introduction: The provision of health care services is not dedicated to promoting
8	42	maintenance of function and does not target frail older persons at high risk of the main
9	43	causes of morbidity and mortality. The aim of this study is to evaluate the effects of a
10	44	proactive medical and social intervention in comparison with conventional care to a group of
11 12		
13	45	persons aged 75 and older selected by statistical prediction.
14	46	Methods and analysis: In a pragmatic multicentre primary care setting (n = 1600), a
15	47	prediction model to find elderly (75+) persons at high risk of complex medical care or
16	48	hospitalisation is used, followed by proactive medical and social, in comparison to usual
17		
18	49	care. The study started in April 2017 with a run-in period until December 2017, followed by a
19 20	50	two-year continued intervention phase that will continue until the end of December 2019. The
20 21	51	intervention includes several tools (multi-professional team for rehabilitation, social support,
22	52	medical care home visits, telephone support etc.). Primary outcome measures are:
23	53	healthcare cost, number of hospital care episodes, hospital care days and mortality.
24	54	Secondary outcomes are: number of outpatient visits, cost of social care and informal care,
25	55	number of prescribed drugs, health-related quality of life (HRQoL), cost-effectiveness, sense
26	56	of security, functional status and ability. We also study the care of elderly persons in a
27	57	broader sense, covering the perspectives of the patients, the professional staff and of the
28	58	management and political level, by using semi-structured interviews, qualitative methods and
29 30	59	a questionnaire.
30 31	29	a questionnaire.
32	60	Ethics and dissemination: Approved by the regional ethical review board in Linköping (Dnr
33	61	2016/347-31). The results will be presented in scientific journals and scientific meetings
34	62	during 2019–2022 and are planned to be used for the development of future care models.
35	02	during 2019-2022 and are planned to be used for the development of future care models.
36	63	Trial registration. Enhanced primary care for the elderly. Clinical Trials Gov ID:
37	64	NCT03180606
38 39	01	
39 40	65	Key words. care frail elderly
41		
42	66	
43		
44	67	
45	60	
46	68	
47 48	69	
40 49	05	
50	70	
51		
52	71	Strengths and limitations of the study
53		
54	72	• This study is a pragmatic clinical trial on proactive healthcare for people 75 years and
55 56	73	older in primary care, meaning that it has a close connection with clinical reality,
56 57	74	which will enhance any future implementation
58	75	• The case-finding method is a statistical prediction model which allows the "screening"
59	76	of large numbers of patients
60	-	

2	
3 4	
5	
5 6 7 8	
8	
9 10	
10	
12	
13 14	
15	
16 17	
11 12 13 14 15 16 17 18	
19 20	
20	
22	
21 22 23 24	
25	
25 26 27	
28	
29 30	
31	
32 33	
34	
35 36 37	
37	
38 39	
40	
41 42	
43	
44 45	
43 46	
47	
48 49	
50 51	
51 52	
53	
54 55	
56	
57 58	

- The developed clinical evaluation and management model integrates primary care
   with community care and social services
  - The project also focuses on the perspectives of the patients, the professionals in the healthcare system and the governance mechanisms, which may explain the perceived shortcomings of today's healthcare for the elderly
  - A fairly long run-in period due to clinical realities and organisational inertia in the healthcare system as well as a long intervention period of two years are clinical necessities, but this increases the risk of non-controlled influences on the project

#### INTRODUCTION

The healthcare situation of the elderly is a challenge for healthcare systems in many countries, and healthcare providers struggle to meet the needs of a growing number of older people<sup>1</sup>. In Sweden, the largest consumers of medical services (60%) are persons 80 years and older (15% of the population), a group that is predicted to increase by 50% over the next 15 years. Several studies report that a majority of the aged population is satisfied with their health<sup>2</sup>, manage life at home and consider themselves healthy<sup>34</sup>. Only a minority of the aged population is in need of hospital care. In most cases, the healthcare system does not distinguish between different groups among the heterogeneous old-age population; instead, both hospital and primary care are organised using a passive and reactive (acting when symptoms or problems occur) approach. There have been many attempts to define and measure frailty among the elderly in order to detect persons with significant care needs (e.g.<sup>5</sup>). However, "frailty" is difficult to define as a medical condition and there is no consensus on the operational definition of the concept <sup>6</sup>. Three major frailty models have been suggested: physical frailty model, deficit accumulation model of frailty, and the biopsychosocial or multidimensional model 7. Furthermore, evaluation using clinical instruments requires and trained staff for each individual evaluation, which is not easily applied within a broader clinical context that lacks a primary geriatric perspective (e.g. primary care and acute ward disciplines). 

The current healthcare system in many countries is not designed to identify individuals with healthcare needs or to direct care resources towards those with the greatest need for care prior to hospitalisation. Since the use of "frailty scales" involves merely a fraction of the flow of hospitalised elderly, statistical prediction models have been proposed as an effective means of evaluating larger target groups to enable resource-limited interventions for those with the greatest needs <sup>8</sup>. However, the clinical use of prediction in routine clinical primary care of the elderly remains to be clarified. Proactive interventions provided to the elderly within a certain age-range, and/or with multi-morbidity but with low predictive value for hospitalisation, may direct healthcare resources towards groups that are not in most need of them. Likewise, interventions for small, specific groups (e.g. newly hospitalised, specific medical diagnoses or patients above a certain frailty index score) will neglect large groups of elderly in need of healthcare or miss the larger care-flows of geriatric hospital care. 

This study will evaluate whether a proactive primary care intervention into a predicted risk population of the elderly results in care that is more effective and of higher quality than that of a control group who receive standard care. In addition, in a set of parallel sub-studies, factors that may facilitate or act as barriers to the development of healthcare for older persons will be studied from several perspectives, including those of the elderly themselves and of the healthcare of the elderly. 

#### METHOD AND ANALYSIS The study consists of two parallel lines of research. The first, linked to the primary scientific question, is an intervention study of proactive care for older persons in primary care. The

second is a set of sub-studies on different perspectives of elderly care, ranging from the patient, the professionals and governance to societal aspects. An overview of the project and

- time-line is presented in Fig. 1.
- Insert figure 1 here. Overview of the project over time

#### Patient involvement

The public was represented health care politicians with responsibility for health care for elderly. They supervised, participated in the construction of and approved the aims and the contents of the study. They follow they progress of the project every 6 months. The patient's perspective of the study is obtained by in-depth interviews at different time points of the study.

#### Intervention study of proactive care for older persons in primary care

#### Primary scientific question

Can the prediction of frail older individuals at high risk of hospital care, combined with proactive healthcare, lead to a decrease in healthcare utilisation and costs?

#### Design, randomisation and setting

This intervention study is designed to follow a shift in the paradigm of elderly care that had already been decided by the care providers. This led us to use a study design that enables us to detect the real-world effectiveness of the intervention in a broad patient group in a real. non-selected clinical context with clinically meaningful outcome parameters. Consequently, our design follows a selected pragmatic clinical trial model, in which defined primary care health centres using the new work routines constitute our intervention group and the remaining centres are used as controls 9. 

The pragmatic clinical trial follows the fact that the intervention to be provided is close to the future modus operandi of healthcare for the elderly, but it still allows a scientific evaluation before it is implemented further in healthcare organisations. It is a prospective, controlled, multicentre study performed in primary care centres in south-east Sweden. A case-finding algorithm (prediction for hospital care) is used to identify eligible persons within the whole population in the region. The intervention will be performed at nine selected primary care centres (provided by the sponsoring County Council of Östergötland), and the predicted patients there form the intervention group. A similar number of control patients with similar 

risk scores (for hospitalisation) are predicted in healthcare centres with similar characteristics

finding algorithm was used in the selection and the patients with the highest risk scores were

included until the preferred number of patients was reached. There was no randomisation of

to the intervention centres, but they receive care as usual, and these centres are not made

aware of the control patients. There is no randomisation at the patient level, but the case-

healthcare centres; these were provided by the healthcare sponsor (County Council of

Östergötland). The control healthcare centres were matched in terms of location (city,

countryside), size and socio-economic distribution. A pre-study analysis of the primary

outcome measures of the two patient groups revealed no significant differences between

### 179 Sample size

them.

A pilot study (not published) showed that 60% of the target population had at least one hospitalisation during a 12-month period. The hypothesis is that this figure will be reduced by 20% in the intervention group in this study. A sample size calculation based on this reduction, a power of 0.8 and a significance level of 0.05 led to a minimum of 270 participants per group. Considering the frail and elderly population, we estimate a 40% drop-out rate and we have therefore increased the sample size to 378 per group. Since we are using a pragmatic clinical trial design, featuring heterogeneity within both the participating population and the participating healthcare centres, this reduces the likelihood of detecting meaningful changes; therefore, it is reasonable to double the number of participants per group, giving a final number of 800 included individuals per group. 

35 190 

# 37 191 Prediction of patient cases 38

The prediction model is described elsewhere (manuscript submitted). In short, the data was obtained between November 2015 and October 2016 from the computerised information system of the County Council of Östergötland, where statistics for all the healthcare in the county is stored. For example, for the whole population there are records of: number of visits to primary or hospital care, number of days in hospital, diagnostic codes for each visit, etc. We used an in-ward hospital stay between November 2016 and January 2017 as the dependent variable. The prediction variables are based on a previous study<sup>4</sup>, including number of GP visits and International Classification of Diseases, 10th Revision, (ICD-10) codes, use of assistive technology, emergency room (ER) visits, age and gender. The aim is to identify participants aged 75 or older who are likely to be hospitalised during the next three months. Risk scores were calculated for all individuals using logistic regression. Individuals were ranked according to the risk scores (for hospital care), from high to low. A cut-off value was chosen so that 800 individuals from the participating healthcare centres with the highest scores were selected for proactive intervention for a period of two years. The same cut-off value was then used to choose individuals from the control healthcare centres. 

## <sup>60</sup> 208 **Evaluation form**.

A four-page evaluation form has been developed and is used to standardise the evaluation of

each individual (the Primary Care Assessment Tool for the Elderly- PASTEL). The goal is to create a time-efficient, easy-to-use tool for a doctor-nurse team. It is intended to be used by primary care nurses and doctors with different levels of experience. The PASTEL form is based on the holistic approach of Comprehensive Geriatric Assessment (CGA)<sup>6</sup>, which can be regarded as combination of diagnostic and therapeutic processes where problems are identified and managed. The assessments cover medical, psychiatric, functional, and social domains required to enable a multifaceted therapeutic plan. It also includes the Clinical Frailty Scale<sup>10</sup>. The form contains three parts. The first consists of an interview guide with mostly multiplechoice questions and a self-rating of health. The second part is a checklist for a brief physical examination and laboratory testing, a medication review and questions about the individual's opinion about their present and future needs for care. The third part is used for a team meeting to make a common estimation of frailty and to decide on the need for further investigation and actions to support the elderly person in order to enhance recovery and promote independence. Intervention The intervention group is approached by a primary care team, who evaluates the client's social and medical condition and establishes a proactive care plan for individuals in need. The primary care team is represented by the general practitioner (GP) responsible for the patient, a registered nurse (RN) dedicated to elderly care and, when needed, a physiotherapist, occupational therapist and/or social worker. The proactive intervention consists of a complete check-up/follow-up and intervention into medical, psychiatric, functional and social aspects of the client in a stepwise, resource-differentiated way according to needs based on the clinical judgement of the team (Fig. 2). Insert figure 2 here. Overview of the intervention The evaluation process used communication over the phone as well as visits to the primary care centre, depending on the priority of the client's needs. Examples of common actions/measures are: evaluation of medication, initiation of home care, diet counselling, advice on physical activity and support for loneliness and isolation. The formation of an "elderly team" with dedicated nurses who function as personal nurses for the frail individuals is the key component of the intervention, together with the standardised evaluation of frailty based on comprehensive geriatric assessment. **Outcome measures for intervention** Primary outcome measures are: healthcare cost, number of hospital care episodes, hospital care days and mortality. Secondary outcomes are: number of outpatient visits, cost of social care and informal care, number of drugs, number of prescribed drugs not recommended for For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- - the elderly, health-related quality of life (HRQoL), cost-effectiveness, sense of security and functional ability.

Data on healthcare consumption will be obtained from the administrative healthcare database and data on healthcare costs from the cost-per-patient database. Costs for social care and informal care are collected from the "Questionnaire for the patient's perspective and in-depth patient data" (see below) and will be estimated by number of contacts multiplied by a defined unit cost. Use of medications at the group level will be studied by extracting group data from the National Medication Database, before, during and after the study. 

#### Statistical analysis for intervention study

Primary and secondary outcome measures for intervention vs control population will consist of analyses for completed year 1 and 2 respectively, using the intention to treat (ITT) and last observation carried forward (LOCF) method. Differences in means and proportions between groups will be analysed using a t-test. Differences in categorical data will be analysed using a Chi-squared test. If the baseline mean risk score differs between the intervention and control groups, primary outcomes adjusted for risk score will be analysed using linear or logistic regression. 

#### Monitoring

Every six months, each primary care centre is monitored by the project group, providing opportunities for dialogue and problem solving. Every six months, or earlier when needed, each primary care centre reviews the patients included in the study and actions are considered depending on the results of the review. Every six months, the primary care teams gather for a network meeting to discuss common issues and share experiences. 

#### Data management

No biomaterials are included in the study. All patient data will be processed lawfully according to the General Data Protection Regulation (GDPR). The data file used for the prediction model, for the intervention group and the control group was retrieved from Region Östergötland's administrative databases. The data file that will be used for analysis in both the main study and the sub-studies contains personal data from Region Östergötland's administrative databases as well as data reported by the patient. The file will only be available to the overall project manager and individuals responsible for each sub-project, i.e. the co-authors of this paper. The file will be stored in databases with a high level of security at Region Östergötland and Linköping University and also protected by personal passwords. Questions regarding data are replied to through the corresponding author upon request. We used the SPIRIT reporting guidelines <sup>11</sup>. 

#### Sub-studies on different perspectives of elderly care, from patient to professionals and governance to societal aspects.

#### **Scientific questions**

What are the experiences of the previous and new healthcare model for older people from a wider individual, social, professional and societal perspective? What are the governance mechanisms that may facilitate or act as barriers to the development of healthcare for older people? What is the cost-effectiveness of the intervention in comparison to care as usual? 

Based on these overall questions, there are four main research perspectives with specific research questions: 

- 1. The perspective of the older patients and their families: How does the change in healthcare provision towards proactive primary elderly care impact upon individual participation and subjective well-being as well as objective indicators of quality of life beyond health? How does the change in healthcare provision towards proactive primary elderly care shape the receipt of informal help and support from spouses, offspring and the wider network? These research questions are studied through a questionnaire from the patient's perspective and interviews from the patient's perspective.
  - 2. The professional perspective on the healthcare system: How does the change in healthcare provision towards proactive primary elderly care change the satisfaction and support of the professionals within the healthcare system? The methods used are qualitative studies of selected parts of the healthcare system, and implementation studies (see below). An implementation study explores the organisational readiness to implement the new work routines in primary care. Investigating organisational readiness can provide knowledge about early factors that are important for implementation.
    - 3. The governance perspective: What are the mechanisms and explanations for today's elderly care, from the political level down to operative healthcare management? The methods used are implementation studies using semi-structured interviews.
    - 4. Cost-effectiveness: What is the cost-effectiveness of the intervention compared to usual care? Data will be collected through questionnaires concerning patient health related outcomes and from administrative registries of health care consumption and costs.

## Methods for sub-studies

Questionnaire for the patient's perspective and in-depth patient data. We will study how the change in healthcare provision impacts upon individual well-being, the support they receive from their private networks of families and friends and their satisfaction with and the support of the healthcare system. A longitudinal study design enables us to follow changes over time. Moreover, we will analyse whether the focusing of care contributes to the life-course accumulation of (dis)advantage in old age and how this contributes to social inequality dynamics. The longitudinal patient questionnaire study collects data on three occasionsover a period of 36 months: baseline before intervention, after completed year 1 and 2, respectively. The information from the questionnaires will be combined with a registry-based 

BMJ Open

1 2		
3	339	assessment of social-structure and life-course information at baseline and referenced with
4	340	nationally representative life-course data on health, occupation and family from Statistics
5 6	341	Sweden (SCB) and the National Board of Health and Welfare (Socialstyrelsen). Measures in
6 7	342	the questionnaire include the EQ-5D-3L and EQ-VAS <sup>12</sup> for health-related quality of life
8	343	(HRQoL) estimates, activities of daily living/functions by the ADL Staircase <sup>13</sup> and RAND-36
9	344	for self-reported functional health <sup>14</sup> . A measure for sense of security in care is also used
10	345	(SECP) <sup>15</sup> . The dizziness handicap inventory is used to detect the presence of a risk of falls
11 12	346	<sup>16</sup> and its related health consequences. A visual analogue scale (0–100 mm) and a pain-
12	347	drawing instrument is used to evaluate pain experience <sup>17</sup> .
14		ů i i
15	348	
16 17	240	Interviews from the patient's perspective. In one sub-project, we focus on how frail older
17 18	349 350	people experience care services if included in the intervention. Twenty semi-structured
19	351	interviews with elderly patients will be conducted. A selection of elderly patients will be made,
20	352	and this selection will include patients who have experiences of the intervention. Interviews
21	353	are intended to provide access to the feelings, thoughts and experiences of the intervention. The
22 23	353	starting point is that the interview is a knowledge-producing activity, and it is during the
24	355	interview and in the interaction with the individual and the researcher that knowledge is
25	356	produced <sup>18</sup> . Another sub-project aims to investigate how the elderly experience their
26	357	everyday lives and the opportunities for rehabilitation from an availability and participation
27 28	358	perspective. Do the elderly receive the rehabilitation they consider themselves to need? A
20	359	qualitative study with a strategic selection of approximately 20 participants from the
30	360	intervention group will be conducted.
31	500	
32 33	361	
34	262	Qualitative studies of selected nexts of the backhown sustains. A suclitative suprassis
35	362	Qualitative studies of selected parts of the healthcare system. A qualitative approach
36	363	(shadowing) <sup>19</sup> is used to study the working conditions for nurses in primary care in relation to
37	364 265	challenges in their professional responsibility connected to their work. The proposed sub-
38 39	365	project addresses key issues in order to obtain knowledge about how competence levels and the distribution of tasks match the needs of frail older people living at home. The ongoing
40	366 367	development in the field of the care of older people can be studied through the concept of
41	368	task-shifting <sup>20</sup> . Questions of task shifting are implicit in discussions concerning the
42	369	relationship between general competence and specialist competence within professional
43 44	370	groups or the resource deficit in relation to ageing populations. The main aim is therefore to
45	370	explore and characterise task-shifting processes in practices, competencies, responsibilities
46	371	and roles from the perspective of registered nurses working within the main project. A
47	372	second aim is to explore the challenges of handling drugs and the pharmaceutical
48 49	373	preparations related to nurse practices in home care, and how these challenges are
49 50	375	processed.
51	575	P
52	376	Implementation studies. In order to meet the future challenges posed by an ageing
53 54	377	population, it is not only important to develop and evaluate new care models, but also to
55	378	ensure that these models are implemented successfully by organisations providing care.
56	379	Three separate studies investigate the implementation of the new work routines for improved
57	380	care among the frail elderly.
		<b>o i</b>
58 59		
58 59 60	381 382	To study the implementation of the model, the project will use a framework that specifies four types (or domains) of determinants, which function as barriers and/or facilitators for

1		
1 2		
2	202	augeocoeful implementation. Because in implementation existing has established that
4	383 384	successful implementation. Research in implementation science has established that successful implementation depends on an interplay between these determinants: (1) the
5	385	effectiveness of the strategies chosen to support the implementation; (2) the characteristics
6	386	of the new practices (routines, methods, etc.) being implemented; (3) beliefs, attitudes and
7	387	motivations among the front-line implementers; and (4) the context of the implementation.
8	388	The framework will provide a basic structure of interviews which will be carried out with
9	389	representatives of different levels of the healthcare system: from political leadership and
10	390	primary-care management to practitioners on the front line of primary care. Study I focuses
11	390 391	on the role of professionals in implementing the new work routines, including adopting a
12	391	holistic approach to care. This study also investigates readiness to change at both an
13	392	individual level (e.g. resources, attitudes) and an organisational level (e.g. system that
14	393 394	support change).
15	395	support change).
16 17	396	Study II. Preliminary results from Study I indicate that successful collaboration between
17	397	primary care providers and the municipalities is essential in achieving proactive care and
19	398	implementing the new work routines. Indeed, most care of the frail elderly occurs outside of a
20	399	primary care setting. The second study therefore investigates these conditions or
21	400	collaborations via interviews with managers representing both organisations. A concept
22	401	mapping approach will be used to identify and quantify the factors affecting implementation.
23	402	Interviews will be audio-recorded and transcribed verbatim.
24	403	
25	404	Finally, a third study will focus on investigating the governance mechanisms that influence
26	405	the present situation as well as the uptake of new models through policy-making and
27	406	implementation. Despite good intentions and various policies, Swedish elderly care has not
28	407	undergone any extensive change; thus, the same challenges and development needs are
29	408	being discussed today as 20 years ago.
30	409	
31 32	410	For this reason, this sub-project will investigate the mechanisms that facilitate or impede
32 33	411	evidence-based policy-making and implementation from the political level to the regional
34	412	level in elderly care. Questions that will be studied are: What influences policy-making and
35	413	implementation at different levels? What are the strategies for policy implementation? How is
36	414	policy implementation monitored and evaluated at different levels? Three levels of policy-
37	415	making and implementation will be studied. Level 1: politicians and Ministry of Health and
38	416	Social Affairs. Level 2: state agencies and authorities at national level, i.e. NBHW
39	417	(Socialstyrelsen) and the Swedish Association of Local Authorities and Regions. Level 3:
40	418	politicians, executive boards and managers at county council and regional level. Interviews
41	419	will be audio-recorded and transcribed verbatim.
42	420	
43	421	Cost-effectiveness. A cost-effectiveness analysis will also be performed. The primary
44 45	422	outcome in the analysis is the incremental cost-effectiveness ratio (ICER): cost/quality
45 46	423	adjusted life year (QALY). The QALY-weights for the analysis will be derived from the EQ-
40 47	424	5D-3L, and the QALYs will be calculated by multiplying the QALY-weight with time. The
48	425	analysis will have a societal perspective meaning that all relevant costs will be included in the
49	426	analysis. Health care utilization and costs will be retrieved from administrative databases.
50	427	Information on social care and informal care will be retrieved from the questionnaire. The
51	428	cost-effectiveness analysis will be performed with a short-term perspective (within trial), and
52	429	also with a life-time perspective applying health economic decision modelling.
53	430	
54	431	
55	122	
56	432	
57	433	Statistical analysis for sub-studies
58 59	-55	
59 60		
		11

**BMJ** Open

The outcomes of the sub-studies are: number of outpatient visits, cost of social and informal

care, number of drugs, number of prescribed drugs not recommended for the elderly, health-

related quality of life (HRQoL), cost-effectiveness, sense of security and functional ability.

The measures will be analysed for years 1 and 2 respectively using the intention to treat

be analysed using a t-test. We intend to estimate the cost-effectiveness in terms of

The QALY weights will be obtained from the EQ-5D-3L.

(ITT) and last observation carried forward (LOCF) method. Differences between groups will

cost/QALY (quality-adjusted life years) from a lifetime perspective using simulation models.

## 16 443 Time plan

An overview is presented in Fig. 1. The project started with the development of the case-finding algorithm (manuscript in progress) in 2017. Based on this model, the case-finding process was undertaken at the beginning of March 2017. Selected patients were presented to each healthcare centre for the start of the intervention programme in April 2017. A run-in period of April-December 2017 was used, during which healthcare centres were informed about and introduced to the new work model, and patients were subsequently enrolled onto the programme. All selected high-risk patients will have received an initial healthcare and/or social care plan. More than 90% of the selected patients were included by the end of December 2017. The intervention/follow-up period is planned to last for two years, until the end of 2019 (Fig 1). 

An initial questionnaire was sent to all selected patients in the intervention and control healthcare centres during May–June 2017. The guestionnaire will also be distributed to enrolled participants in years 2 and 3. Interviews with professionals in participating primary care health centres and communities were performed during June-September 2017. Interviews with elderly participants in order to capture the patient's perspective on the study were performed during December 2017–July 2018. Interviews with elderly participants in order to capture the patient's perspective on rehabilitation will take place during November 2018-February 2019. Interviews with high-level decision-makers and politicians were conducted during January-September 2018. 

A first preliminary outcome analysis after 13 months of intervention will be performed in 2019. The intervention and collection of healthcare data ends on 31 December 2019. The analysis of primary and secondary outcome measures starts in 2020. The scientific writing-up and participation in academic conferences has already started for some of the sub-projects. The writing period for the intervention study begins in spring 2020. Dialogue with owners/stakeholders at a political level takes place every six months during the course of the project. 

Possible evidence for changes in elderly care across the whole County of Östergötland will
 be available in autumn 2020, when the implementation process of the new care model can
 be broadened. Members of the research group are participating in workshops at a national
 level concerning healthcare development.

- 58 474
- 60 475

## 3 476 **Ethics and dissemination**

This study was subject to ethical evaluation and approved by the regional ethical review board in Linköping (Dnr 2016/347-31). They judged all aspects of the study including design and safety. By adding an academic study to an ongoing change in the healthcare process for the elderly, we do not per se include or exclude treatment possibilities for individuals or groups of individuals. The study itself is "inert" within the healthcare system. Therefore, we do not see that the use of aggregated patient data from the healthcare system can be of any harm to the participants. On the contrary, we find strong ethical motives for the study, which is an academic attempt to detect the real-world effectiveness of a politically determined intervention into a large patient group. The patients who responded to the questionnaire did so using an informed consent. 

The data will be presented in scientific journals and communicated at scientific meetings during the period 2018–2022. The outcome data of the study will be presented to the healthcare provider (County Council of Östergötland) for a discussion on the evidence relating to future care models for elderly persons. The data will also be used by healthcare managers and decision-makers for the development of future care models.

#### DISCUSSION Clinical trials on complex healthcare processes are rare and difficult to design with adequate scientific quality. On the other hand, delimited clinical trials may also only be valid within an academic setting and the outcome difficult to reproduce in clinical reality. In order to counteract the scientific challenges facing trials in complex clinical settings and processes, the use of a pragmatic clinical trial design is one, or perhaps the only, alternative <sup>9</sup>. In terms of the primary context of elderly care, this study is intended to find answers to basic scientific questions about the future healthcare of the elderly. One challenge for the study was to find older patients in need of healthcare, hopefully before escalating needs would develop. Managing thousands of patients during this screening for possible illness may be impossible in healthcare using face-to-face methods. Statistical models for case findings have recently proven valid and are recommended in the clinical healthcare of old persons <sup>8</sup> so this modus operandi was used in this study. There is a great need for improved healthcare for the elderly and a simultaneous knowledge gap regarding scientific data on what care models to use in the future. This study aims to fill some of that gap and may hopefully generate some clinically meaningful data that can be used for the future development of healthcare for older persons. **Authors contributions** All authors have made substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data. They have participated in the drafting the work or revising it critically for important intellectual content. The gave final approval of the version published. Jan Marcusson: principal investigator, design, analysis and scientific writing. Magnus Nord: clinical project leader, design, clinical site visits, data collection, analysis, scientific writing Ylva Böttiger: design, analysis, scientific writing Huan-Ji Dong: design and analysis of prediction model. Scientific writing. Maria Johansson, Anneli Peolsson: clinicians and scientists responsible for rehabilitation, design of the postal questionnaire, data collection, analysis, scientific writing Jenny Alwin, Lars-Åke Levin: design and health economic analysis, design of the postal questionnaire, data collection, analysis, scientific writing Petra Dannapfel, Kristin Thomas, Bonnie Poksinska, design and analysis of implementation studies, data collection, analysis, scientific writing Annette Sverker, Anna Olaison, Elisabet Cedersund, design of interviews and analysis of the patient's perspective, scientific writing

2		
3	529	Susanne Kelfve, Andreas Motel-Klingebiel: design of postal questionnaire, analysis of well-
4	530	being, network support, satisfaction and social inequality based on questionnaire and registry
5	531	data, scientific writing
6	221	
7	532	Ingrid Hellström, Agneta Kullberg: design and analysis of professional perspective, scientific
8		
9	533	writing
10	534	Johan Lyth analysis, scientific writing
11 12	554	Jonan Lyth analysis, Scientific whiting
12	535	Malin Wass, project-coordinator, scientific writing
14	555	Main Wass, project-coordinator, scientific writing
15	536	Agneta Andersson: co-investigator, analysis, scientific writing
16	550	Agricia / Indersson. do Investigator, analysis, scientine writing
17	537	
18	557	
19	538	
20		
21	539	Funding statement
22		
23	540	This work was supported by the County Council of Östergötland and Linköping University
24	541	from the strategic research fund for 'Health Care and Welfare' [Grant number 2016186-14].
25	542	Contact person is Dean Johan Söderholm, Deans office, Medical Faculty, Linköping
26		University. This funding source had no role in the design of this study and will not have any
27	543	
28	544	role during its execution, analyses, interpretation of the data, or decision to submit results.
29	- 4-	
30 31	545	Competing interests: None.
32	546	
33	540	Competing interests: None.
34	547	
35	547	
36	548	
37	510	
38		
39		
40		
41		
42		
43 44		
44 45		
45 46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56 57		
57 58		
58 59		
60		

2		
3	549	
4	545	
5	550	REFERENCES
6		
7 8	551	1. Banerjee S. Multimorbidity—older adults need health care that can count past one. Lancet
o 9	552	neurology 2015;385(9967):587-89. doi: doi:10.1016/S0140-6736(14)61596-8
10	553	2. Soong J, Poots AJ, Scott S, et al. Developing and validating a risk prediction model for acute care
11	554	based on frailty syndromes. BMJ open 2015;5(10):e008457. doi: 10.1136/bmjopen-2015-
12	555	008457 [published Online First: 2015/10/23]
13	556	3. Collerton J, Davies K, Jagger C, et al. Health and disease in 85 year olds: baseline findings from the
14	557	Newcastle 85+ cohort study. Bmj 2009;339:b4904. doi: 10.1136/bmj.b4904 [published Online
15	558	First: 2009/12/24]
16 17	559	4. Nagga K, Dong HJ, Marcusson J, et al. Health-related factors associated with hospitalization for old
18	560	people: comparisons of elderly aged 85 in a population cohort study. Archives of gerontology
19	561	and geriatrics 2012;54(2):391-7. doi: 10.1016/j.archger.2011.04.023 [published Online First:
20	562	2011/06/07]
21	563	5. Edmans J, Bradshaw L, Franklin M, et al. Specialist geriatric medical assessment for patients
22	564	discharged from hospital acute assessment units: randomised controlled trial. <i>Bmj</i>
23	565	2013;347:f5874. doi: 10.1136/bmj.f5874 [published Online First: 2013/10/10]
24 25	566	6. Ellis G, Whitehead MA, Robinson D, et al. Comprehensive geriatric assessment for older adults
25 26	567	admitted to hospital: meta-analysis of randomised controlled trials. <i>Bmj</i> 2011;343:d6553.
20	568	doi: 10.1136/bmj.d6553 [published Online First: 2011/10/29]
28	569	7. Panza F, Lozupone M, Solfrizzi V, et al. Different Cognitive Frailty Models and Health- and
29	570	Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. Journal of
30	571	Alzheimer's disease : JAD 2018;62(3):993-1012. doi: 10.3233/JAD-170963 [published Online
31	572	First: 2018/03/23]
32	573	8. NICE. National Institute for Clinical Excellence. Multimorbidity: clinical assessment and
33 34	574	management (NICE clinical guideline 56), 2016.
35	575	9. Ford I, Norrie J. Pragmatic Trials. <i>New England Journal of Medicine</i> 2016;375:454-63. doi:
36	576 577	10.1056/NEJMra1510059 10. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly
37	578	people. CMAJ : Canadian Medical Association journal = journal de l'Association medicale
38	579	canadienne 2005;173(5):489-95. doi: 10.1503/cmaj.050051 [published Online First:
39	580	2005/09/01]
40	580 581	11. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items
41 42	582	for clinical trials. Annals of internal medicine 2013;158(3):200-7. doi: 10.7326/0003-4819-
43	583	158-3-201302050-00583 [published Online First: 2013/01/09]
44	584	12. EuroQol G. EuroQola new facility for the measurement of health-related quality of life. <i>Health</i>
45	585	policy 1990;16(3):199-208. [published Online First: 1990/11/05]
46	586	13. Sonn U, Asberg KH. Assessment of activities of daily living in the elderly. A study of a population
47	587	of 76-year-olds in Gothenburg, Sweden. Scandinavian journal of rehabilitation medicine
48	588	1991;23(4):193-202. [published Online First: 1991/01/01]
49 50	589	14. Orwelius L, Nilsson M, Nilsson E, et al. The Swedish RAND-36 Health Survey - reliability and
50	590	responsiveness assessed in patient populations using Svensson's method for paired ordinal
52	591	data. J Patient Rep Outcomes 2017;2(1):4. doi: 10.1186/s41687-018-0030-0 [published
53	592	Online First: 2017/01/01]
54	593	15. Krevers B, Milberg A. The instrument 'sense of security in carepatients' evaluation': its
55	594	development and presentation. <i>Psycho-oncology</i> 2014;23(8):914-20. doi: 10.1002/pon.3502
56	595	16. Jacobson GP, Calder JH. A screening version of the Dizziness Handicap Inventory (DHI-S). <i>The</i>
57	596	American journal of otology 1998;19(6):804-8. [published Online First: 1998/11/27]
58 59	597	17. Margolis RB, Tait RC, Krause SJ. A Rating System for Use with Patient Pain Drawings. <i>Pain</i>
60	598	1986;24(1):57-65. doi: Doi 10.1016/0304-3959(86)90026-6


2 3 4 5 6 7 8	599 600 601 602 603
$\begin{array}{c} 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 9\\ 20\\ 122\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 132\\ 33\\ 45\\ 36\\ 7\\ 38\\ 9\\ 40\\ 142\\ 43\\ 45\\ 46\\ 7\\ 48\\ 9\\ 50\\ 51\\ \end{array}$	602
52 53 54 55 56 57	
58	


1


599 18. Patton MQ. Qualitative research & evaluation methods. London: SAGE 2002

- 600 19. Macdonald S. Studying actions in a context: a qualitative shadowing method for organizational
   601 research. *Qualitative research* 2005;5:455-73.
- 602 20. WHO. Task shifting: Rational redistribution of tasks among health workforce teams: Global
   603 recommendations and guidelines. Geneva: World Health Organization, 2008.

to beet teriew only







# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

 Page
 Number

 Title
 #1
 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
 1

 Trial registration
 #2a
 Trial identifier and registry name. If not yet registered, name of intended registry
 2

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2	Trial registration:	<u>#2b</u>	All items from the World Health Organization Trial	n/a
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	data set		Registration Data Set	
	Protocol version	<u>#3</u>	Date and version identifier	n/a
	Funding	<u>#4</u>	Sources and types of financial, material, and other support	15
	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	1, 14
	responsibilities:			
	contributorship			
	Roles and	<u>#5b</u>	Name and contact information for the trial sponsor	15
22 23 24	responsibilities:			
24 25 26	sponsor contact			
20 27 28 29	information			
30 31 32 33	Roles and	<u>#5c</u>	Role of study sponsor and funders, if any, in study design;	15
	responsibilities:		collection, management, analysis, and interpretation of	
34 35	sponsor and funder		data; writing of the report; and the decision to submit the	
36 37 38			report for publication, including whether they will have	
39 40			ultimate authority over any of these activities	
41 42				
43 44	Roles and	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating	14
45 46	responsibilities:		centre, steering committee, endpoint adjudication	
47 48	committees		committee, data management team, and other individuals or	
49 50			groups overseeing the trial, if applicable (see Item 21a for	
51 52 53			data monitoring committee)	
54 55	Background and	<u>#6a</u>	Description of research question and justification for	4-5
56 57 58	rationale		undertaking the trial, including summary of relevant studies	
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3			(published and unpublished) examining benefits and harms for each intervention	
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	Background and rationale: choice of	<u>#6b</u>	Explanation for choice of comparators	5-6
	comparators			
	Objectives	<u>#7</u>	Specific objectives or hypotheses	5
	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel	5
			group, crossover, factorial, single group), allocation ratio,	
			and framework (eg, superiority, equivalence, non-inferiority,	
			exploratory)	
	Study setting	<u>#9</u>	Description of study settings (eg, community clinic,	5
	<i>y</i> 0		academic hospital) and list of countries where data will be	
			collected. Reference to where list of study sites can be	
			obtained	
	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable,	6
		<u></u>	eligibility criteria for study centres and individuals who will	Ū
			perform the interventions (eg, surgeons, psychotherapists)	
42 43				_
44 45 46	Interventions:	<u>#11a</u>	Interventions for each group with sufficient detail to allow	7
47 48	description		replication, including how and when they will be	
49 50			administered	
51 52 53	Interventions:	<u>#11b</u>	Criteria for discontinuing or modifying allocated	n/a
54 55	modifications		interventions for a given trial participant (eg, drug dose	
56 57			change in response to harms, participant request, or	
58 59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2018-027847 on 22 May 2019. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

1 2			improving / worsening disease)	
3 4 5 6 7 8 9	Interventions:	<u>#11c</u>	Strategies to improve adherence to intervention protocols,	n/a
	adherance		and any procedures for monitoring adherence (eg, drug	
			tablet return; laboratory tests)	
10 11 12	Interventions:	<u>#11d</u>	Relevant concomitant care and interventions that are	n/a
13 14 15	concomitant care		permitted or prohibited during the trial	
16 17	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the	7
18 19 20			specific measurement variable (eg, systolic blood pressure),	
20 21 22			analysis metric (eg, change from baseline, final value, time	
23 24			to event), method of aggregation (eg, median, proportion),	
25 26			and time point for each outcome. Explanation of the clinical	
27 28 29			relevance of chosen efficacy and harm outcomes is strongly	
30 31			recommended	
32 33 34	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any	11-12
35 36			run-ins and washouts), assessments, and visits for	
37 38 39			participants. A schematic diagram is highly recommended	
40 41 42			(see Figure)	
42 43 44	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study	6
45 46			objectives and how it was determined, including clinical and	
47 48			statistical assumptions supporting any sample size	
49 50 51			calculations	
52 53 54	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to	n/a
55 56			reach target sample size	
57 58				
59 60	I	For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Allocation: sequence	<u>#16a</u>	Method of generating the allocation sequence (eg,	n/a
3 4 5 6	generation		computer-generated random numbers), and list of any	
			factors for stratification. To reduce predictability of a random	
7 8 9			sequence, details of any planned restriction (eg, blocking)	
10 11			should be provided in a separate document that is	
12 13			unavailable to those who enrol participants or assign	
14 15 16 17			interventions	
18 19	Allocation	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg,	n/a
20 21	concealment		central telephone; sequentially numbered, opaque, sealed	
22 23	mechanism		envelopes), describing any steps to conceal the sequence	
24 25 26			until interventions are assigned	
27 28 29 30 31	Allocation:	<u>#16c</u>	Who will generate the allocation sequence, who will enrol	n/a
	implementation		participants, and who will assign participants to	
32 33 34			interventions	
35 36	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg,	n/a
37 38 39			trial participants, care providers, outcome assessors, data	
39 40 41 42			analysts), and how	
43 44	Blinding (masking):	<u>#17b</u>	If blinded, circumstances under which unblinding is	n/a
45 46	emergency		permissible, and procedure for revealing a participant's	
47 48 49	unblinding		allocated intervention during the trial	
50 51 52	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline,	8
53 54			and other trial data, including any related processes to	
55 56			promote data quality (eg, duplicate measurements, training	
57 58 59			of assessors) and a description of study instruments (eg,	
59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2018-027847 on 22 May 2019. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

1 2 3 4 5 6 7			questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	
, 8 9	Data collection plan:	<u>#18b</u>	Plans to promote participant retention and complete follow-	n/a
10 11	retention		up, including list of any outcome data to be collected for	
12 13			participants who discontinue or deviate from intervention	
14 15 16			protocols	
17 18	Data management	#19	Plans for data entry, coding, security, and storage, including	8
19 20	Data managoment	<u>" 10</u>	any related processes to promote data quality (eg, double	0
21 22			data entry; range checks for data values). Reference to	
23 24 25			where details of data management procedures can be	
26 27			found, if not in the protocol	
28 29				
30 31	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary	8
32 33 34			outcomes. Reference to where other details of the statistical	
35 36			analysis plan can be found, if not in the protocol	
37 38	Statistics: additional	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and	n/a
39 40 41	analyses		adjusted analyses)	
42 43	Ctatiatian analysis	#20-	Definition of each reis non-ulation relating to protocol non	2
44 45	Statistics: analysis	<u>#20c</u>	Definition of analysis population relating to protocol non-	n/a
46 47	population and		adherence (eg, as randomised analysis), and any statistical	
48 49	missing data		methods to handle missing data (eg, multiple imputation)	
50 51 52	Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC); summary	8
53 54	formal committee		of its role and reporting structure; statement of whether it is	
55 56			independent from the sponsor and competing interests; and	
57 58			reference to where further details about its charter can be	
59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			found, if not in the protocol. Alternatively, an explanation of	
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39			why a DMC is not needed	
	Data monitoring:	<u>#21b</u>	Description of any interim analyses and stopping guidelines,	12
	interim analysis		including who will have access to these interim results and	
			make the final decision to terminate the trial	
	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing	n/a
			solicited and spontaneously reported adverse events and	
			other unintended effects of trial interventions or trial conduct	
	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any,	8
			and whether the process will be independent from	
			investigators and the sponsor	
		#0.4		10
	Research ethics	<u>#24</u>	Plans for seeking research ethics committee / institutional	12
	approval		review board (REC / IRB) approval	
	Protocol	<u>#25</u>	Plans for communicating important protocol modifications	n/a
	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
			relevant parties (eg, investigators, REC / IRBs, trial	
40 41 42			participants, trial registries, journals, regulators)	
43 44 45	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential	12
45 46 47			trial participants or authorised surrogates, and how (see	
48 49			Item 32)	
50 51 52	Consent or assent:	#26b	Additional consent provisions for collection and use of	12
52 53 54		<u>#200</u>	participant data and biological specimens in ancillary	12
55 56	ancillary studies			
57 58			studies, if applicable	
59 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2018-027847 on 22 May 2019. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

1 2	Confidentiality	<u>#27</u>	How personal information about potential and enrolled	n/a
3 4			participants will be collected, shared, and maintained in	
5 6			order to protect confidentiality before, during, and after the	
7 8 9			trial	
10 11 12	Declaration of	<u>#28</u>	Financial and other competing interests for principal	15
13 14 15	interests		investigators for the overall trial and each study site	
16 17 18	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset,	8
19 20			and disclosure of contractual agreements that limit such	
21 22			access for investigators	
23 24 25	Ancillary and post	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for	n/a
26 27	trial care		compensation to those who suffer harm from trial	
28 29 30			participation	
31 32	Dissemination policy:	<u>#31a</u>	Plans for investigators and sponsor to communicate trial	12-13
33 34 35	trial results		results to participants, healthcare professionals, the public,	
36 37			and other relevant groups (eg, via publication, reporting in	
38 39			results databases, or other data sharing arrangements),	
40 41 42			including any publication restrictions	
43 44 45	Dissemination policy:	<u>#31b</u>	Authorship eligibility guidelines and any intended use of	n/a
45 46 47	authorship		professional writers	
48 49 50	Dissemination policy:	<u>#31c</u>	Plans, if any, for granting public access to the full protocol,	n/a
51 52	reproducible		participant-level dataset, and statistical code	
53 54	research			
55 56 57	Informed consent	#32	Model consent form and other related documentation given	n/a
58 59				n/a
60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 0 11 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 3 3 4 5 6 7 8 9 0 11 2 3 3 4 5 6 7 8 9 0 11 2 3 3 4 5 6 7 8 9 0 11 2 3 3 4 5 6 7 8 9 0 11 2 3 3 4 5 6 7 8 9 0 11 2 3 3 4 5 6 7 8 9 0 11 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	materials	to participants and authorised surrogates
	Biological specimens #33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicablen/a
	The SPIRIT checklist is distri	buted under the terms of the Creative Commons Attribution License CC-
	BY-ND 3.0. This checklist can be completed online using https://www.goodreports.org/, a tool made	
		collaboration with Penelope.ai
	For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml